Mechanism and Research Progress of miR-21 in Breast Cancer
10.3971/j.issn.1000-8578.2024.24.0433
- VernacularTitle:miR-21在乳腺癌中的作用机制及研究进展
- Author:
Rui WANG
1
;
Yufeng WANG
2
;
Quanlin GUAN
3
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
2. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China;Department of Breast Disease, Gansu Provincial Cancer Hospital, Lanzhou 730000, China.
3. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China;Department of Oncology Surgery, First Hospital of Lanzhou University, Lanzhou 730000, China.
- Publication Type:REVIEWS
- Keywords:
Breast cancer;
miR-21;
MicroRNAs;
Signaling pathway;
PTEN;
PDCD4
- From:
Cancer Research on Prevention and Treatment
2024;51(12):1051-1056
- CountryChina
- Language:Chinese
-
Abstract:
As a highly heterogeneous disease, breast cancer ranks first in new cases and deaths of female malignant tumors. In recent years, the incidence of breast cancer increases and tends to be younger. Early-onset breast cancer (<40 years old) is mostly associated with adverse biological characteristics and poor prognosis. Although immunotherapy and targeted therapy have advances in the treatment of breast cancer, a major challenge of neoplastic resistance to systemic therapy remains. Therefore, early diagnostic markers and potential therapeutic targets with high specificity and sensitivity must be identified. miR-21 affects the occurrence and development of breast cancer by targeting related genes and regulating related signaling pathways (PTEN/PI3K/Akt and NF-κB/ miR-21-5p/PDCD4 signaling pathways). This paper reviews the mechanism and progress of miR-21 in breast cancer.
